Qadri Uksim, Zaffar Sofiya, Wani Saleem Javaid, Roohi Shugufta, Aman Munazah, Bhat Sabah, Majid Umaya
Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India.
Department of General Medicine, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India.
Iran J Microbiol. 2024 Dec;16(6):732-736. doi: 10.18502/ijm.v16i6.17245.
The incidence of multidrug-resistant, Gram-negative organisms, isolated as the etiological agents of infections is ascending. The advent of novel antibiotics poses significant challenges, necessitating the optimization and utilization of extant antimicrobial agents. Cefoperazone, a third-generation cephalosporin and β-lactam antimicrobial, when combined with sulbactam, an irreversible β-lactamase inhibitor, mitigates the vulnerability of cefoperazone to β-lactamase-producing organisms. Nonetheless, regional data on the susceptibility patterns for this pharmacological combination remains scarce. The primary objective of this investigation was to assess the efficacy of the cefoperazone-sulbactam combination against prevalent Gram-negative bacteria isolated from blood cultures.
A total of 700 Gram-negative isolates, comprising species, and were procured using the BacT/Alert 3D system. The identification and susceptibility testing for cefoperazone-sulbactam were performed using the VITEK Compact ID and AST system. Comparative analysis was conducted against other tested antibiotics.
The study revealed that cefoperazone-sulbactam exhibited commendable activity against Gram-negative pathogens isolated from blood, surpassed only by colistin and tigecycline.
Cefoperazone-sulbactam demonstrates robust activity against the most frequently encountered clinical pathogens, suggesting its potential as an efficacious therapeutic agent. The findings underscore the imperative for ongoing surveillance of resistance patterns and trends among commonly used antimicrobials.
作为感染病原体分离出的耐多药革兰氏阴性菌的发病率正在上升。新型抗生素的出现带来了重大挑战，需要优化和利用现有的抗菌药物。头孢哌酮是一种第三代头孢菌素和β-内酰胺类抗菌药物，与不可逆β-内酰胺酶抑制剂舒巴坦联合使用时，可减轻头孢哌酮对产β-内酰胺酶生物的易感性。尽管如此，关于这种药物组合的药敏模式的区域数据仍然很少。本研究的主要目的是评估头孢哌酮-舒巴坦组合对从血培养中分离出的常见革兰氏阴性菌的疗效。
使用BacT/Alert 3D系统共获得700株革兰氏阴性菌分离株，包括 种和 。使用VITEK Compact ID和AST系统对头孢哌酮-舒巴坦进行鉴定和药敏试验。对其他测试抗生素进行了比较分析。
研究表明，头孢哌酮-舒巴坦对从血液中分离出的革兰氏阴性病原体表现出值得称赞的 活性，仅次于黏菌素和替加环素。
头孢哌酮-舒巴坦对最常见的临床病原体表现出强大的活性，表明其作为一种有效治疗药物的潜力。研究结果强调了持续监测常用抗菌药物耐药模式和趋势的必要性。
